City View Green Holdings Past Earnings Performance
Past criteria checks 0/6
City View Green Holdings has been growing earnings at an average annual rate of 50.2%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 46.6% per year.
Key information
50.2%
Earnings growth rate
82.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 46.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How City View Green Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -2 | 1 | 0 |
| 31 Mar 24 | 0 | -2 | 1 | 0 |
| 31 Dec 23 | 0 | -2 | 1 | 0 |
| 30 Sep 23 | 0 | -1 | 1 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -5 | 2 | 0 |
| 30 Jun 22 | 0 | -5 | 2 | 0 |
| 31 Mar 22 | 0 | -5 | 2 | 0 |
| 31 Dec 21 | 0 | -5 | 2 | 0 |
| 30 Sep 21 | 0 | -4 | 3 | 0 |
| 30 Jun 21 | 0 | -6 | 5 | 0 |
| 31 Mar 21 | 0 | -5 | 5 | 0 |
| 31 Dec 20 | 0 | -6 | 5 | 0 |
| 30 Sep 20 | 0 | -9 | 4 | 0 |
| 30 Jun 20 | 0 | -8 | 3 | 0 |
| 31 Mar 20 | 0 | -10 | 4 | 0 |
| 31 Dec 19 | 0 | -25 | 4 | 0 |
| 30 Sep 19 | 0 | -20 | 4 | 0 |
| 30 Jun 19 | 0 | -21 | 3 | 2 |
| 31 Mar 19 | 0 | -20 | 2 | 2 |
| 31 Dec 18 | 0 | -4 | 2 | 2 |
Quality Earnings: CVGR is currently unprofitable.
Growing Profit Margin: CVGR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CVGR is unprofitable, but has reduced losses over the past 5 years at a rate of 50.2% per year.
Accelerating Growth: Unable to compare CVGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVGR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: CVGR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.